Goldman Sachs ActiveBeta ... (GSSC)
63.44
0.01 (0.02%)
At close: Apr 01, 2025, 3:59 PM
63.48
0.06%
After-hours: Apr 01, 2025, 06:59 PM EDT
0.02% (1D)
Bid | 60.17 |
Market Cap | 542.49M |
AUM | 482.31M |
NAV | 64.56 |
EPS (ttm) | 4.19 |
PE Ratio (ttm) | 15.14 |
Shares Out | 8.55M |
Inception Date | Jul 10, 2017 |
Ask | 67.44 |
Volume | 22.06K |
Open | 63.25 |
Previous Close | 63.43 |
Day's Range | 62.66 - 63.78 |
52-Week Range | 60.23 - 77.00 |
Holdings | 1.36K |
Expense Ratio | 0.20% |
About GSSC
The fund seeks to achieve its investment objective by investing at least 80% of its assets in securities included in its index, in depositary receipts representing securities included in the index and in underlying stocks in respect of depositary receipts included in its index. The index is designed to deliver exposure to equity securities of small capitalization U.S. issuers.
Asset Class Equity
Ticker Symbol GSSC
Inception Date Jul 10, 2017
Provider Goldman Sachs
Website Fund Home Page
Top Sectors
Sector | Weight % |
---|---|
Financial Services | 18.31% |
Industrials | 16.31% |
Healthcare | 16.16% |
Technology | 13.85% |
Consumer Cyclical | 11.39% |
Top 10 Holdings 4.96% of assets
Name | Symbol | Weight |
---|---|---|
Corcept Therapeutics... | CORT | 0.97% |
Sprouts Farmers Mark... | SFM | 0.77% |
USD U.s. Dollar | - | 0.47% |
Mueller Industries, ... | MLI | 0.45% |
Commvault Systems, I... | CVLT | 0.41% |
Mr. Cooper Group Inc... | COOP | 0.40% |
Applied Industrial T... | AIT | 0.40% |
Alkermes Plc | ALKS | 0.39% |
Catalyst Pharmaceuti... | CPRX | 0.36% |
Tg Therapeutics, Inc... | TGTX | 0.34% |
Dividends Dividend Yield 1.47%
Ex-Dividend | Amount | Payment Date |
---|---|---|
Mar 25, 2025 | $0.1755 | Mar 31, 2025 |
Dec 23, 2024 | $0.4371 | Dec 30, 2024 |
Sep 24, 2024 | $0.1164 | Sep 30, 2024 |
Jun 24, 2024 | $0.2301 | Jun 28, 2024 |
Mar 22, 2024 | $0.1959 | Mar 28, 2024 |

3 weeks ago · seekingalpha.com
Why Is The IPO Market Struggling? Here's What Active Managers Have To SayStrong returns in U.S. stocks, particularly over the past two plus years, have led investors to question the relative lack of companies going public via the IPO process — as well as the potential impl...